Purdue Pharma L.P.
http://www.purduepharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Purdue Pharma L.P.
Sumitomo Pharma To Cut 400 US Employees Amid Latuda LOE
After reducing 500 employees last year while reorganizing its subsidiaries in the US in the aftermath of patent expiration for its mainstay product Latuda, the Japanese firm has decided to move ahead with another rationalization affecting 400 employees there.
US FDA Says Opioid Database Firm With Purdue Pharma Connections Reported No Conflicts
Amid criticism of its contract to evaluate opioid data from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) survey programs, the FDA says federal databases lack the necessary information on opioid misuse.
Opioid Abuse Groups Criticize US FDA For Using Purdue Pharma-Connected Data Firm
The advocates say the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) and its Substance Abuse Treatment Center Programs Combined Survey has conflicts of interest, as well as a connection to the infamous maker of OxyContin.
Asia Deal Watch: Dr Reddy’s Licenses Coya’s ALS Combo Drug
Plus deals involving Abbisko/Merck & Co., Astellas/Phenomic AI, PRISM Biolab/Lilly and WuXi Biologics/Myricx.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Nutraceuticals
- OTC, Consumer
-
Drug Delivery
- Controlled Release
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Imbrium Therapeutics L.P.
- Adlon Therapeutics L.P
- Rhodes Pharmaceuticals LP
- CoCensys Inc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice